Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14

Blood

Volumn 89, Issue 12, 1997, Pages 4268-4274

  Park, C Thomas ^a   Creasey, Abla A ^b   Wright, Samuel D ^b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; BINDING PROTEIN; CD14 ANTIGEN; ESCHERICHIA COLI ENDOTOXIN; SALMONELLA ENDOTOXIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ADHESION; CONTROLLED STUDY; HUMAN; HUMAN CELL; INFLAMMATION; NEUTROPHIL; PRIORITY JOURNAL;

EID: 0030926515     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.12.4268     Document Type: Article

References (33)

1. Warr TA, Rao LV, Rapaport SI: Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: Effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. Blood 75:1481, 1990
2. Broze GJ Jr: Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 46:103, 1995
3. Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ Jr: Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patients samples. Blood 78:387, 1991
4. Sandset PM, Warn-Cramer BJ, Maki SL, Rappaport SI: Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Shwartzman reaction. Blood 78:1496, 1991
5. Sandset PM, Warn-Cramer BJ, Rao LV, Maki SL, Rappaport SI: Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbit to disseminated intravascular coagulation induced with tissue factor: Evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci USA 88:708, 1991
6. Creasey AA, Chang ACK, Feigen L, Wun T-C, Taylor FB Jr, Hinshaw LB: Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 91:2850, 1993
7. Carr C, Bild GS, Chang ACK, Peer GT, Palmier MO, Frazier RB, Gustafson ME, Wun T-C, Creasey AA, Hinshaw LB, Taylor FB Jr, Galluppi GR: Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock. Circ Shock 44:126, 1995
8. Taylor FB Jr, Chang ACK, Peer GT, Mather T, Blick K, Catlett R, Lockhart MS, Esmon CT: DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage. Blood 78:364, 1991
9. Hailman E, Lichenstein HS, Wurfel MM, Miller DS, Johnson DA, Kelley M, Busse LA, Zukowski MM, Wright SD: Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J Exp Med 179:269, 1994
10. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249:1431, 1990
11. Hailman E, Vasselon T, Kelley M, Busse LA, Hu MCT, Lichenstein HS, Detmers PA, Wright SD: Stimulation of macrophages and neutrophils by complexes of lipopolysaccharide and soluble CD14. J Immunol 156:4384, 1996
12. Frey EA, Miller DA, Jahr TG, Sundan A, Bazil V, Espevik T, Finlay BB, Wright SD: Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med 176:1665, 1992
13. Schumann RR, Leong SR, Flaggs GW, Gray PW. Wright SD, Mathison JC, Tobias PS, Ulevitch RJ: Structure and function of lipopolysaccharide binding protein. Science 249:1429, 1990
14. Park CT, Wright SD: Plasma lipopolysaccharide-binding protein is found associated with a particle conatining apolipoprotein A-I, phospholipid and factor H-related proteins. J Biol Chem 271:18054, 1996
15. Yu B, Wright SD: Catalytic properties of lipopolysaccharide (LPS) binding protein - Transfer of LPS to soluble CD14. J Biol Chem 271:4100, 1996
16. Diaz-Collier JA, Palmier MO, Kretzmer KK, Bishop BF, Combs RG, Obukowicz MG, Frazier RB, Bild GS, Joy WD, Hill SR, Duffin KL, Gustafson ME, Junger KD, Grabner RW, Galluppi GR, Wun T-C: Refold and characterization of recombinant tissue factor pathway inhibitor expressed in Escherichia coli. Thromb Haemost 71:339, 1994
17. Wurfel MM, Kunitake ST, Lichenstein H, Kane JP, Wright SD: Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med 180:1025, 1994
18. Van Kessel KPM, Park CT, Wright SD: A fluorescence microassay for the quantitation of integrin-mediated adhesion of neutrophil. J Immunol Methods 172:25, 1994
19. Hailman E, Albers JJ, Wolfbauer G, Tu AY, Wright SD: Neutralization and transfer of lipopolysaccharide by phospholipid transfer protein. J Biol Chem 271:12172, 1996
20. Tobias PS, Soldau K, Gegner JA, Mintz D, Ulevitch RJ: Lipopolysaccharide binding protein-mediated complexation of lipopolysaccharide with soluble CD14. J Biol Chem 270:10482, 1995
21. Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze GJ Jr: Functional significance of the Kunitz-type domains of lipoprotein-associated coagulation inhibitor. Nature 338:518, 1989
22. Wesselschmidt R, Likert K, Huang Z, MacPhail L, Broze GJ Jr: Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coag Fibrinol 4:661, 1993
23. 243, of the third Kunitz domain is a heparin-binding site. Biochemistry 34:5725, 1995
24. Bajaj MS, Rana SV, Wysolmerski RB, Bajaj SP: Inhibitor of the factor VIIa-tissue factor complex is reduced in paients with disseminated intravascular coagulation but not in patients with severe hepatocellular disease. J Clin Invest 79:1874, 1987
25. Sandset PM, Roise O, Aasen AO, Abildgaard U: Extrinsic pathway inhibitor in postoperative/posttraumatic septicemia: Increased levels in fatal cases. Haemostasis 19:189, 1989
26. Warr TA, Rao LV, Rapaport SI: Human plasma extrinsic pathway inhibitor activity: II. Plasma levels in disseminated intravascular coagulation and hepatocellular disease. Blood 74:994, 1989
27. Brandtzaeg P, Sandset PM, Waage A, Mollnes TE, Ovstebo R, Joo GB, Abildgaard U, Kierulf P: Human tissue factor pathway inhibitor increase in shock and severe DIC is associated with vessel wall damage induced by extreme endotoxemia. Thromb Haemost 69:681, 1993
28. Takahashi H, Sato N, Shibata A: Plasma tissue factor pathway inhibitor in disseminated intravascular coagulation: Comparison of its behavior with plasma tissue factor. Thromb Res 80:339, 1995
29. Sabharwal AK, Bajaj SP, Ameri A, Tricomi SM, Hyers TM, Dahms TE, Taylor FB Jr, Bajaj MS: Tissue factor pathway inhibitor and von Willebrand factor antigen levels in adult respiratory distress syndrome and in a primate model of sepsis. Am J Respir Crit Care Med 151:758, 1996
30. Carson SD, Haire WD, Broze GJ Jr, Novotny WF, Pirrucello SJ, Duggan MJ: Lipoprotein associated coagulation inhibitor, factor VII, antithrombin III, and monocyte tissue factor following surgery. Thromb Haemost 66:534, 1991
31. Ameri A, Kuppuswamy MN, Basu S, Bajaj SP: Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood 79:3219, 1992
32. Rana SV, Reimers HJ, Pathikonda MS, Bajaj SP: Expression of tissue factor and factor VIIa/tissue factor inhibitor activity in endotoxin or phorbol ester stimulated U937 monocyte-like cells. Blood 71:259, 1988
33. McGee MP, Foster S, Wang X: Simultaneous expression of tissue factor and tissue factor pathway inhibitor by human monocytes. A potential mechanism for localized control of blood coagulation. J Exp Med 179:1847, 1994